MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
1.090
-0.020
-1.80%
Opening 13:02 02/09 EST
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.140
LOW
1.065
VOLUME
170.23K
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
1.065
MARKET CAP
27.37M
P/E (TTM)
-0.5525
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDCX last week (0202-0206)?
Weekly Report · 8h ago
Weekly Report: what happened at MDCX last week (0126-0130)?
Weekly Report · 02/02 10:00
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Medicus Pharma Ltd (MDCX)
TipRanks · 01/29 17:20
Weekly Report: what happened at MDCX last week (0119-0123)?
Weekly Report · 01/26 10:00
Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License
TipRanks · 01/22 23:07
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel
Reuters · 01/22 18:42
BUZZ-U.S. STOCKS ON THE MOVE-Autodesk, Teledyne, Alphabet
Reuters · 01/22 16:02
BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital
Reuters · 01/22 14:11
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.